Form 4: Guardant Health Director Receives Equity Awards

Guardant Health Director Alex M. Azar II was granted stock options and restricted stock units totaling 17,136 shares, vesting over four years.

Summary

• Alex M. Azar II, a Director of Guardant Health, Inc. (GH), was granted equity awards on September 12, 2025.
• The awards include 10,532 stock options with an exercise price of $54.895 per share and an expiration date of September 12, 2035.
• Additionally, 6,604 Restricted Stock Units (RSUs) were granted.
• Both the stock options and RSUs vest over a four-year period, with 25% vesting on the one-year anniversary of September 12, 2025, and the remaining 75% vesting monthly over the subsequent three years.
• Following these transactions, Alex M. Azar II beneficially owns 10,532 stock options and 6,604 Restricted Stock Units directly.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive signal as it aligns management's interests with shareholders, promoting long-term value creation. It is a routine compensation event rather than a direct financial performance indicator.

Positives

• The grant of equity awards aligns the Director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The multi-year vesting schedule encourages sustained commitment and strategic oversight from the Director.

Negatives

• The awards are not an immediate cash investment by the director, meaning the value is contingent on future stock price performance and continued service.
• The exercise price of the stock options ($54.895) means the options will only have intrinsic value if the stock price rises above this level.

Risks

• The value of the stock options and RSUs is subject to the market price fluctuations of Guardant Health's common stock.
• Vesting of the awards is contingent upon continued service, meaning the Director must remain with the company for the full four-year period to realize the full benefit.
• There is a risk that the company's stock price may not appreciate above the option exercise price, rendering the options worthless.

Future Outlook

The equity awards are designed to incentivize the Director's long-term commitment and contribution to Guardant Health's strategic objectives and shareholder value creation over the four-year vesting period.

Industry Context

The granting of stock options and restricted stock units to directors is a standard practice in publicly traded companies, particularly within the biotechnology and healthcare sectors, to attract and retain talent and align leadership interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The equity grants align the Director's incentives with shareholder interests, potentially leading to better long-term strategic decisions and increased shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options and RSUs will begin vesting on September 12, 2026 (one-year anniversary of the grant date).
• The remaining 75% of the awards will vest monthly over the subsequent three years.
• The Director may exercise vested stock options at any time before their expiration date of September 12, 2035.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation grant to a director, which is a standard practice for aligning interests. It does not contain new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in an investment recommendation based on fundamental analysis. Therefore, a 'hold' recommendation is appropriate as this event alone does not alter the investment thesis.

Keywords

Guardant Health, GH, Alex M. Azar II, Form 4, SEC filing, stock option, RSU, equity award, director compensation, insider transaction